BRPI0721988A2 - interferon alfa 2a modificado por polietileno glicol, a preparação e uso do mesmo. - Google Patents

interferon alfa 2a modificado por polietileno glicol, a preparação e uso do mesmo.

Info

Publication number
BRPI0721988A2
BRPI0721988A2 BRPI0721988A BRPI0721988A BRPI0721988A2 BR PI0721988 A2 BRPI0721988 A2 BR PI0721988A2 BR PI0721988 A BRPI0721988 A BR PI0721988A BR PI0721988 A BRPI0721988 A BR PI0721988A BR PI0721988 A2 BRPI0721988 A2 BR PI0721988A2
Authority
BR
Brazil
Prior art keywords
modified
preparation
polyethylene glycol
interferon alfa
alfa
Prior art date
Application number
BRPI0721988A
Other languages
English (en)
Inventor
Bin Liu
Fenghong Yin
Li Sun
Lifang Lei
Lu Zhuang
Min Liu
Qingjiang Xiao
Song Lin
Tiebing Wang
Weidong Zhou
Original Assignee
Biosteed Gene Expression Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosteed Gene Expression Tech Co Ltd filed Critical Biosteed Gene Expression Tech Co Ltd
Publication of BRPI0721988A2 publication Critical patent/BRPI0721988A2/pt
Publication of BRPI0721988B1 publication Critical patent/BRPI0721988B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BRPI0721988-1A 2007-09-04 2007-09-04 Interferon alfa 2a modificado por polietileno glicol, método para preparação e uso do mesmo, e composição. BRPI0721988B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2007/002643 WO2009030065A1 (zh) 2007-09-04 2007-09-04 聚乙二醇修饰的干扰素α2a及其制备方法和应用

Publications (2)

Publication Number Publication Date
BRPI0721988A2 true BRPI0721988A2 (pt) 2016-10-18
BRPI0721988B1 BRPI0721988B1 (pt) 2021-07-27

Family

ID=40428421

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0721988-1A BRPI0721988B1 (pt) 2007-09-04 2007-09-04 Interferon alfa 2a modificado por polietileno glicol, método para preparação e uso do mesmo, e composição.

Country Status (12)

Country Link
US (1) US8597634B2 (pt)
EP (1) EP2196475B1 (pt)
KR (1) KR101483814B1 (pt)
CN (1) CN101636411B (pt)
BR (1) BRPI0721988B1 (pt)
CA (1) CA2698396C (pt)
DK (1) DK2196475T3 (pt)
ES (1) ES2386575T3 (pt)
PL (1) PL2196475T3 (pt)
PT (1) PT2196475E (pt)
WO (1) WO2009030065A1 (pt)
ZA (1) ZA201001555B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008002399A1 (es) 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
CA2698173C (en) * 2007-09-04 2015-02-03 Biosteed Gene Expression Tech. Co., Ltd. Interferon alpha 2b modified by polyethylene glycol, the preparation and use thereof
CN101636411B (zh) 2007-09-04 2013-01-09 厦门伯赛基因转录技术有限公司 聚乙二醇修饰的干扰素α2a及其制备方法和应用
CN111053918A (zh) * 2011-09-05 2020-04-24 韩美科学株式会社 一种包含干扰素α-缀合物的抗癌用药物组合物
CA2964390A1 (en) 2014-11-06 2016-05-12 Pharmaessentia Corporation Dosage regimen for pegylated interferon
CN106924752B (zh) * 2015-12-30 2021-11-09 北京大学 制备蛋白质-聚氨基酸偶联物的方法
CN116120424A (zh) * 2022-06-06 2023-05-16 江苏靶标生物医药研究所有限公司 一种干扰素α2b可溶性重组表达和分离纯化方法及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US6610830B1 (en) * 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
CN1243779A (zh) 1998-07-31 2000-02-09 东莞中镇鞋材有限公司 纤维板及其制造方法
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
WO2003076490A1 (en) 2002-03-13 2003-09-18 Beijing Jiankai Technology Co., Ltd. Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound
AU2002356422A1 (en) * 2002-11-01 2004-05-25 Cadila Healthcare Limited Mthod for producing recombinant human interferon alpha 2b polypeptide in pichia pastoris
AU2003293668A1 (en) * 2002-11-15 2004-06-15 F. Hoffmann-La Roche Ag Positional isomers of peg ifn alpha 2a
CA2698173C (en) * 2007-09-04 2015-02-03 Biosteed Gene Expression Tech. Co., Ltd. Interferon alpha 2b modified by polyethylene glycol, the preparation and use thereof
CN101636411B (zh) 2007-09-04 2013-01-09 厦门伯赛基因转录技术有限公司 聚乙二醇修饰的干扰素α2a及其制备方法和应用

Also Published As

Publication number Publication date
ZA201001555B (en) 2010-11-24
KR20100063108A (ko) 2010-06-10
EP2196475B1 (en) 2012-06-06
CA2698396C (en) 2014-01-21
US20100239532A1 (en) 2010-09-23
WO2009030065A8 (zh) 2009-09-11
EP2196475A4 (en) 2010-10-20
BRPI0721988B1 (pt) 2021-07-27
CN101636411A (zh) 2010-01-27
EP2196475A1 (en) 2010-06-16
WO2009030065A1 (zh) 2009-03-12
CA2698396A1 (en) 2009-03-12
PT2196475E (pt) 2012-09-07
DK2196475T3 (da) 2012-09-17
PL2196475T3 (pl) 2012-10-31
ES2386575T3 (es) 2012-08-23
US8597634B2 (en) 2013-12-03
CN101636411B (zh) 2013-01-09
KR101483814B1 (ko) 2015-01-16

Similar Documents

Publication Publication Date Title
LTC2380592I2 (lt) Antagonistinis antikūnas, nukreiptas prieš su kalcitonino genu susijusį peptidą
BRPI0806589A2 (pt) Catalisador, sua preparação e uso.
BRPI0821276A2 (pt) Produto, e, uso do produto
DE602005011765D1 (de) Transponder mit mehreren betriebsarten
IL205127A0 (en) Humanized a?? antibody, composition comprising the same and uses thereof
DE602006008118D1 (de) Entfernungsanordnung mit distaler freigabe
EP2578631A4 (en) RESIN COMPOSITION AND PREPREG AND LAMINATED FILM THEREWITH
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0818641A2 (pt) Rótulo, e, uso do rótulo
BRPI0911772A2 (pt) composto, composição farmacêutica, e, uso do composto.
GB2458080B (en) Sterols modified by polyethylene glycol, the preparation and the use thereof
DK2468732T3 (da) 1H-Quinazolin-2,4-dioner
FR2892275B1 (fr) Poudrier.
NO20053147D0 (no) Forsterkningsring.
DK2168197T3 (da) Membran-elektrode-enhed
BRPI0923402A2 (pt) Peptídeos c10rf59 e vacinas incluindo os mesmos.
BRPI0819017A2 (pt) recipiente em plástico transparente de camadas múltiplas moldado por injeção, recipiente obtido por estiragem baixial de um recipiente, conjunto e uso do conjunto
FR2891597B1 (fr) Joint homocinetique a rotule.
FR2918305B3 (fr) Rasoir orientable complete par un element lifting.
JP2006176755A5 (pt)
FR2919703B1 (fr) Vanne d'etranglement.
FR2881644B1 (fr) Composition cosmetique a texture fine.
田辺元 08. Synthetic Geometry, 1.
ITBO20060289A1 (it) Dispositivo di impilamento per fazzoletti, tovaglioli e simili.
ITSS20060006A1 (it) L'intrusa - gioco logico - enigmatico.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 14/56 (2006.01), A61K 47/60 (2017.01), A61K 3

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/09/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.